Payment overview · 2025
General Payments
$344.66
18 reported records · 11 companies
Healthcare provider profile · identity verified
Jackilyn Byrd, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · MOREHEAD, KY · NPI 1982273975
Verified facts
What the public records show
CMS Open Payments records show Jackilyn Byrd, APRN received $344.66 in general payments during 2025 across 18 reported records.
Indivior Inc. accounted for 18.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Farxiga by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Xarelto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Indivior Inc. | Unresolved — no canonical attribution shown | $62.62 | 18.2% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $50.93 | 14.8% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $49.36 | 14.3% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $40.46 | 11.7% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $29.16 | 8.5% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $26.85 | 7.8% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $22.00 | 6.4% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $19.32 | 5.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.52 | 4.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.89 | 4.3% | 1 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $13.55 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $344.66 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $62.62 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $50.93 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $49.36 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $40.46 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $29.16 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $26.85 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $22.00 | 1 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $19.32 | 1 | 2025 |
Source payment records
|
|||||
| INVEGA TRINZA Normalized: invega trinza |
Drug | Janssen Pharmaceuticals, Inc | $19.32 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.89 | 1 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $13.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
81 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 299 | 67 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 240 | 23 |
| Lisinopril | Lisinopril | 236 | 57 |
| Omeprazole | Omeprazole | 222 | 57 |
| Gabapentin | Gabapentin | 216 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 199 | 64 |
| Levothyroxine Sodium | Levothyroxine Sodium | 155 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 145 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 143 | 29 |
| Amlodipine Besylate | Amlodipine Besylate | 135 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 112 | 27 |
| Metformin Hcl | Metformin Hcl | 110 | 30 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 101 | 24 |
| Losartan Potassium | Losartan Potassium | 98 | 26 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 96 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 91 | 22 |
| Trazodone Hcl | Trazodone Hcl | 86 | 21 |
| Buspirone Hcl | Buspirone Hcl | 85 | 19 |
| Sertraline Hcl | Sertraline Hcl | 85 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 82 | 19 |
| Ozempic | Semaglutide | 81 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 81 | 24 |
| Furosemide | Furosemide | 79 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 76 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 72 | 17 |
| Carvedilol | Carvedilol | 69 | 15 |
| Montelukast Sodium | Montelukast Sodium | 69 | 16 |
| Ibuprofen | Ibuprofen | 66 | 17 |
| Amoxicillin | Amoxicillin | 65 | 56 |
| Potassium Chloride | Potassium Chloride | 62 | 22 |
| Meloxicam | Meloxicam | 60 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 59 | 17 |
| Metoprolol Tartrate | Metoprolol Tartrate | 58 | 14 |
| Ondansetron Odt | Ondansetron | 58 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 52 | 18 |
| Prednisone | Prednisone | 52 | 36 |
| Bupropion Hcl Sr | Bupropion Hcl | 51 | 11 |
| Januvia | Sitagliptin Phosphate | 46 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 45 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 43 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 42 | 29 |
| Metformin Hcl Er | Metformin Hcl | 42 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 42 | 13 |
| Xarelto | Rivaroxaban | 42 | suppressed |
| Baclofen | Baclofen | 40 | suppressed |
| Famotidine | Famotidine | 40 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 39 | 31 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 38 | suppressed |
| Eliquis | Apixaban | 36 | suppressed |
| Fluconazole | Fluconazole | 36 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 35 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 34 | 12 |
| Cephalexin | Cephalexin | 33 | 25 |
| Allopurinol | Allopurinol | 32 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 31 | suppressed |
| Clonazepam | Clonazepam | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Roflumilast | Roflumilast | 29 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 28 | 13 |
| Atenolol | Atenolol | 27 | suppressed |
| Jardiance | Empagliflozin | 26 | suppressed |
| Novolog Flexpen | Insulin Aspart | 26 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 25 | suppressed |
| Simvastatin | Simvastatin | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 24 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Alprazolam | Alprazolam | 22 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Vraylar | Cariprazine Hcl | 22 | suppressed |
| Bumetanide | Bumetanide | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Nystatin | Nystatin | 19 | 15 |
| Valsartan | Valsartan | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Repatha Syringe | Evolocumab | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 13 |
| Bupropion Xl | Bupropion Hcl | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 12 |
| Fenofibrate | Fenofibrate,micronized | 17 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Zubsolv | Buprenorphine Hcl/Naloxone Hcl | 16 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 11 |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $344.66 · 18 records | Indivior Inc. | AIRSUPRA, Auvelity, BRIXADI, CAPLYTA, Cologuard Collection Kit, Dexcom G6 Transmitter, INVEGA SUSTENNA, INVEGA TRINZA, REXULTI, SUBLOCADE, VRAYLAR | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Vraylar play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error